BioAlliance says partner Vestiq debuts Oravig in USA

French biotech firm BioAlliance Pharma (Euronext Paris – BIO) has announces the launch of Oravig (miconazole buccal tablets, known as Loramyc in Europe) in the USA by its commercial partner, privately-held Vestiq Pharmaceuticals.

Just a few months after the signature of the license agreement between the two companies, worth a potential $44 million to BioAlliance (The Pharma Letter July 22, 2012), commercial teams have begun the active promotion of Oravig, a treatment for oropharyngeal candidiasis in adults, to US prescribers and wholesalers.

Based in North Carolina, Vestiq is a company dedicated to the commercialization of innovative, effective and safe therapeutic products designed to meet needs of patients requiring specific care. Following the recent acquisition of Praelia Pharmaceuticals by Vestiq, Oravig commercial operations will be driven directly by Praelia, the operational subsidiary. Vestiq has developed a specialized portfolio of therapeutic innovations dedicated to cancer supportive care, among which Oravig, indicated for the treatment of oropharyngeal candidiasis, holds a strategic position.